keyword
MENU ▼
Read by QxMD icon Read
search

Radioembolization

keyword
https://www.readbyqxmd.com/read/28432387/yttrium-90-radioembolization-for-unresectable-combined-hepatocellular-cholangiocarcinoma
#1
Lauren S Chan, Daniel Y Sze, George A Poultsides, John D Louie, Mohammed A Abdelrazek Mohammed, David S Wang
PURPOSE: Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare mixed cell type primary liver cancer with limited data to guide management. Transarterial radioembolization with yttrium-90 microspheres (RE) is an emerging treatment option for both hepatocellular carcinoma and intrahepatic cholangiocarcinoma. This study explored the safety and efficacy of RE for unresectable cHCC-CC. METHODS: Patients with histopathologically confirmed cHCC-CC treated with RE were retrospectively evaluated...
April 21, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28421483/update-on-embolization-therapies-for-hepatocellular-carcinoma
#2
REVIEW
Sirish Kishore, Tamir Friedman, David C Madoff
PURPOSE OF REVIEW: The purpose of the review is to summarize the latest applications for embolotherapy in the management of patients with HCC according to BCLC stage. RECENT FINDINGS: While traditionally reserved for patients with unresectable HCC and stage B disease, there is an important role for embolization therapies in earlier stage patients as an adjunct to ablation, bridging, or downstaging therapy, as a means to improve safety of resection, and potentially as an arterial ablative option in the case of radioembolization...
June 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28418940/assessment-of-the-albumin-bilirubin-albi-grade-as-a-prognostic-indicator-for-hepatocellular-carcinoma-patients-treated-with-radioembolization
#3
Bin Gui, Ashley A Weiner, John Nosher, Shou-En Lu, Gretchen M Foltz, Omar Hasan, Seung K Kim, Vyacheslav Gendel, Naganathan B Mani, Darren R Carpizo, Nael E Saad, Timothy J Kennedy, Darryl A Zuckerman, Jeffrey R Olsen, Parag J Parikh, Salma K Jabbour
OBJECTIVE: As the utility of Child-Pugh (C-P) class is limited by the subjectivity of ascites and encephalopathy, we evaluated a previously established objective method, the albumin-bilirubin (ALBI) grade, as a prognosticator for yttrium-90 radioembolization (RE) treatment for patients with hepatocellular carcinoma (HCC). MATERIALS AND METHODS: A total of 117 patients who received RE for HCC from 2 academic centers were reviewed and stratified by ALBI grade, C-P class, and Barcelona Clinic Liver Cancer stage...
April 17, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28415671/predictors-and-prognosticators-for-survival-with-yttrium-90-radioembolization-therapy-for-unresectable-colorectal-cancer-liver-metastasis
#4
REVIEW
Meaghan S Dendy, Johannes M Ludwig, Hyun S Kim
This critical review aims to explore predictive and prognostic biomarkers of Yttrium-90 (Y90) radioembolization therapy of colorectal liver metastases. A brief overview of established predictive and prognostic molecular and genetic biomarkers in colorectal cancer therapies will be discussed. A review of the literature on imaging modalities, genetic, metabolic and other molecular markers and the subsequent outcomes in post-Y90 treatment will be presented. How these biomarkers and future biomarker research can inform locoregional treatment decisions in the clinical setting of metastatic colorectal cancer lesions of the liver will be explored...
March 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28408731/long-term-outcome-after-liver-transplantation-for-hepatocellular-carcinoma-following-yttrium-90-radioembolization-bridging-treatment
#5
Sonia Radunz, Jürgen Treckmann, Hideo A Baba, Jan Best, Stefan Müller, Jens M Theysohn, Andreas Paul, Tamás Benkö
BACKGROUND Bridging treatments are employed in liver transplant waitlist patients with hepatocellular carcinoma (HCC) because of the risk of tumor progression during the waiting time. Radioembolization is mostly employed in the control of large or multifocal HCCs when other locoregional treatment modalities cannot be applied because of the number or size of lesions. The purpose of this study was to evaluate our experience with the use of radioembolization as a bridge to transplantation and its effect on tumor recurrence and survival after liver transplantation...
April 14, 2017: Annals of Transplantation: Quarterly of the Polish Transplantation Society
https://www.readbyqxmd.com/read/28405728/clinical-feasibility-of-90-y-digital-pet-ct-for-imaging-microsphere-biodistribution-following-radioembolization
#6
Chadwick L Wright, Katherine Binzel, Jun Zhang, Evan J Wuthrick, Michael V Knopp
PURPOSE: The purpose of this study was to evaluate the clinical feasibility of next generation solid-state digital photon counting PET/CT (dPET/CT) technology and imaging findings in patients following (90)Y microsphere radioembolization in comparison with standard of care (SOC) bremsstrahlung SPECT/CT (bSPECT/CT). METHODS: Five patients underwent SOC (90)Y bremsstrahlung imaging immediately following routine radioembolization with 3.5 ± 1.7 GBq of (90)Y-labeled glass microspheres...
April 12, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28365172/segmental-yttrium-90-radioembolization-versus-segmental-chemoembolization-for-localized-hepatocellular-carcinoma-results-of-a-single-center-retrospective-propensity-score-matched-study
#7
Siddharth A Padia, Guy E Johnson, Kathryn J Horton, Christopher R Ingraham, Matthew J Kogut, Sharon Kwan, Sandeep Vaidya, Wayne L Monsky, James O Park, Renuka Bhattacharya, Daniel S Hippe, William P Harris
PURPOSE: To compare segmental radioembolization with segmental chemoembolization for localized, unresectable hepatocellular carcinoma (HCC) not amenable to ablation. MATERIALS AND METHODS: In a single-center, retrospective study (2010-2015), 101 patients with 132 tumors underwent segmental radioembolization, and 77 patients with 103 tumors underwent segmental doxorubicin-based drug-eluting embolic or conventional chemoembolization. Patients receiving chemoembolization had worse performance status (Eastern Cooperative Oncology Group 0, 76% vs 56%; P = ...
March 29, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28357572/safety-and-efficacy-of-y-90-radioembolization-after-prior-major-hepatic-resection
#8
Markus Zimmermann, Maximilian Schulze-Hagen, Martin Liebl, Federico Pedersoli, Fabian Goerg, Tom Florian Ulmer, Alexander Heinzel, Peter Isfort, Christiane Kuhl, Philipp Bruners
PURPOSE: To evaluate the safety and efficacy of yttrium-90 radioembolization (RE) following left or right hepatic lobectomy. MATERIALS AND METHODS: Between 2011 and 2016, 15 patients underwent RE with Y90-resin microspheres following right (8/15) or left (7/15) hepatic lobectomy. In eight patients, the whole liver remnant was treated during a single session, whereas the remaining seven patients received up to 3 selective RE at 1- to 2-month intervals. The administered patient activity was calculated based on the body surface area (BSA) method in all cases...
March 29, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28351831/protocol-for-combined-analysis-of-foxfire-sirflox-and-foxfire-global-randomized-phase-iii-trials-of-chemotherapy-selective-internal-radiation-therapy-as-first-line-treatment-for-patients-with-metastatic-colorectal-cancer
#9
Pradeep S Virdee, Joanna Moschandreas, Val Gebski, Sharon B Love, E Anne Francis, Harpreet S Wasan, Guy van Hazel, Peter Gibbs, Ricky A Sharma
BACKGROUND: In colorectal cancer (CRC), unresectable liver metastases are associated with a poor prognosis. The FOXFIRE (an open-label randomized phase III trial of 5-fluorouracil, oxaliplatin, and folinic acid +/- interventional radioembolization as first-line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer), SIRFLOX (randomized comparative study of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment in patients with nonresectable liver metastases from primary colorectal carcinoma), and FOXFIRE-Global (assessment of overall survival of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment in patients with nonresectable liver metastases from primary colorectal carcinoma in a randomized clinical study) clinical trials were designed to evaluate the efficacy and safety of combining first-line chemotherapy with selective internal radiation therapy (SIRT) using yttrium-90 resin microspheres, also called transarterial radioembolization...
March 28, 2017: JMIR Research Protocols
https://www.readbyqxmd.com/read/28343412/yttrium-90-microsphere-radioembolization-in-unresectable-intrahepatic-cholangiocarcinoma
#10
Cristina Mosconi, Alberta Cappelli, Salvatore Ascanio, Irene Pettinari, Francesco Modestino, Matteo Renzulli, Maria Cristina Galaverni, Alessandro Cucchetti, Annagiulia Gramenzi, Cinzia Pettinato, Rita Golfieri
Intrahepatic cholangiocarcinoma is increasing in frequency worldwide, but radical surgical treatment is practicable in 30-40% of cases. The median survival without therapy is about 8 months, increased to 12 months in combination with systemic chemotherapy. Therefore, locoregional therapies, such as, radiofrequency ablation or transarterial chemoembolization have been employed. Radioembolization with yttrium-90 microspheres ((90)Y-TARE) is a novel intrarterial treatment which could be included in the armamentarium of treatment options, having shown higher median survival (up to 22 months) and low complication rates...
March 27, 2017: Future Oncology
https://www.readbyqxmd.com/read/28342103/survival-and-prognostic-factors-after-adjuvant-131-iodine-labeled-lipiodol-for-hepatocellular-carcinoma-a-retrospective-analysis-of-106-patients-over-20-years
#11
Jonathan Olesinski, François Mithieux, Olivier Guillaud, Marie-Noëlle Hilleret, Catherine Lombard-Bohas, Luc Henry, Olivier Boillot, Thomas Walter, Christian Partensky, Pierre Paliard, Pierre-Jean Valette, Jean-Philippe Vuillez, Françoise Borson-Chazot, Jean-Yves Scoazec, Jérôme Dumortier
OBJECTIVE: Hepatocellular carcinoma (HCC) has high recurrence rate after curative treatment. The aim of the present study was to report our experience with adjuvant use of (131)I-lipiodol after curative treatment of HCC in terms of recurrence and survival in a large cohort of patients with a long follow-up. METHODS: All patients treated with (131)I-lipiodol after curative treatment of HCC in two French centers from 1991 to 2009 were included in a retrospective cohort study...
March 24, 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28323121/the-treatment-of-intermediate-stage-tumour-beyond-tace-from-surgery-to-systemic-therapy
#12
REVIEW
Peter R Galle, Francesco Tovoli, Friedrich Foerster, Marcus A Wörns, Alessandro Cucchetti, Luigi Bolondi
Intermediate stage hepatocellular carcinoma (HCC) comprises the largest subgroup of patients with this disease and is characterized by substantial heterogeneity. Functional liver impairment, total tumour burden and other prognostic factors such as high alpha-fetoprotein serum level, presence of micro-vascular invasion, and poorly differentiated tumours relevantly contribute to outcome. The usage of the standard therapeutic approach, transarterial chemoembolization - TACE, for all intermediate stage HCC patients is probably an over-simplification and may therefore not be appropriate for all patients...
March 17, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28317063/prognostic-value-of-pretreatment-diffusion-weighted-magnetic-resonance-imaging-for-outcome-prediction-of-colorectal-cancer-liver-metastases-undergoing-90y-microsphere-radioembolization
#13
Frederic Carsten Schmeel, Birgit Simon, Julian Alexander Luetkens, Frank Träber, Carsten Meyer, Leonard Christopher Schmeel, Amir Sabet, Samer Ezziddin, Hans Heinz Schild, Dariusch Reza Hadizadeh
PURPOSE: To investigate the clinical potential of pretreatment apparent diffusion coefficient (ADC) on diffusion-weighted magnetic resonance imaging (DWI) for therapy response and outcome prediction in patients with liver-predominant metastatic colorectal cancer (CRC) undergoing radioembolization with (90)Yttrium-microspheres (90Y-RE). METHODS: Forty-six consecutive patients with unresectable CRC liver metastases underwent standardized clinical DWI on a 1.5 T MR scanner prior to and 4-6 weeks after 90Y-RE...
March 19, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28300366/internal-dosimetry-for-radioembolization-therapy-with-yttrium-90-microspheres
#14
Maryam Fallahpoor, Mehrshad Abbasi, Ali Asghar Parach, Faraz Kalantari
The absorbed doses in the liver and adjacent viscera in Yttrium-90 radioembolization therapy for metastatic liver lesions are not well-documented. We sought for a clinically practical way to determine the dosimetry of this advent treatment. Six different female XCAT BMIs and seven different male XCAT BMIs were generated. Using Monte Carlo GATE code simulation, the total of 100MBq (90) Y was deposited uniformly in the source organ, liver. Self-irradiation and absorbed doses in lung, kidney and bone marrow were calculated...
March 2017: Journal of Applied Clinical Medical Physics
https://www.readbyqxmd.com/read/28299645/new-concepts-in-embolotherapy-of-hcc
#15
REVIEW
F Pesapane, N Nezami, F Patella, J F Geschwind
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related deaths worldwide with rapidly growing incidence rates in the USA and Europe. Despite improving surveillance programs, most patients are diagnosed at intermediate to advanced stages and are no longer amenable to curative therapies, such as ablation, surgical resection and liver transplantation. For such patients, catheter-based image-guided embolotherapies such as transarterial chemoembolization (TACE) represent the standard of care and mainstay therapy, as recommended and endorsed by a variety of national guidelines and staging systems...
April 2017: Medical Oncology
https://www.readbyqxmd.com/read/28292478/real-world-data-for-the-evaluation-of-transarterial-radioembolization-versus-sorafenib-in-hepatocellular-carcinoma-a-cost-effectiveness-analysis
#16
Carla Rognoni, Oriana Ciani, Silvia Sommariva, Rosanna Tarricone
OBJECTIVES: To perform a cost-effectiveness analysis comparing the use of transarterial radioembolization (TARE) with that of sorafenib in the treatment of patients with intermediate or advanced hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer staging system. METHODS: Patient-level data were consecutively recorded and collected at three oncology centers in Italy. A propensity score matching was performed to compare patients with similar clinical characteristics who underwent TARE or sorafenib treatment...
March 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28283704/cytokines-and-90-y-radioembolization-relation-to-liver-function-and-overall-survival
#17
Max Seidensticker, Maciej Powerski, Ricarda Seidensticker, Robert Damm, Konrad Mohnike, Benjamin Garlipp, Maurice Klopffleisch, Holger Amthauer, Jens Ricke, Maciej Pech
BACKGROUND: To evaluate the course of pro- and anti-inflammatory cytokines after (90)Y-radioembolization (RE) of liver malignancies and to identify prognosticators for liver-related adverse events and survival. METHODS: In 34 consecutive patients with secondary or primary liver tumors scheduled for RE, the following cytokines were measured prior to and 2 h, 3 days, and 6 weeks after RE: interleukin (IL) -1, IL-2, IL-4, IL-6, IL-8, tumor necrosis factor alpha (TNF-α), and interferon-γ...
March 10, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28280611/baseline-hemoglobin-and-liver-function-predict-tolerability-and-overall-survival-of-patients-receiving-radioembolization-for-chemotherapy-refractory-metastatic-colorectal-cancer
#18
Andrew S Kennedy, David Ball, Steven J Cohen, Michael Cohn, Douglas M Coldwell, Alain Drooz, Edward Ehrenwald, Samir Kanani, Fred M Moeslein, Charles W Nutting, Samuel G Putnam, Steven C Rose, Michael Savin, Sabine Schirm, Navesh K Sharma, Eric Wang
BACKGROUND: Patients with liver metastatic colorectal cancer (mCRC) often benefit from receiving (90)Y-microsphere radioembolization (RE) administered via the hepatic arteries. Prior to delivery of liver-directed radiation, standard laboratory tests may assist in improving outcome by identifying correctable pre-radiation abnormalities. METHODS: A database containing retrospective review of consecutively treated patients of mCRC from July 2002 to December 2011 at 11 US institutions was used...
February 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28268101/downstaging-of-bilobar-hepatocellular-carcinoma-after-radioembolization-with-90-y-microspheres-as-a-bridge-to-liver-transplantation
#19
L Reguera-Berenguer, J Orcajo-Rincón, A Rotger-Regí, A M Matilla-Peña, M Echenagusia-Boyra, R Pérez-Pascual, A Marí-Hualde, J C Alonso-Farto
Hepatic radioembolization with (90)Y is an increasingly widely used locoregional therapy in the treatment of hepatocellular carcinoma. Its potential benefit has recently been described as a downstaging treatment, achieving a decreased tumour burden and allowing patients to be rescued for more radical treatments, such as liver transplantation. The case is presented of a patient diagnosed with multifocal bilobar hepatocellular carcinoma, Barcelona Clinic Liver Cancer (BCLC) intermediate stage, in whom treatment with (90)Y achieved a satisfactory radiological response with a very significant reduction of tumour burden, allowing rescue with liver transplantation...
March 3, 2017: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/28261595/commentary-on-the-article-entitled-hepatocellular-carcinoma-with-macrovascular-invasion-treated-with-yttrium-90-radioembolization-prior-to-transplantation
#20
Wan Yee Lau
No abstract text is available yet for this article.
February 2017: Hepatobiliary Surgery and Nutrition
keyword
keyword
13605
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"